250 related articles for article (PubMed ID: 30861625)
1. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation.
Wienke J; Bellutti Enders F; Lim J; Mertens JS; van den Hoogen LL; Wijngaarde CA; Yeo JG; Meyer A; Otten HG; Fritsch-Stork RDE; Kamphuis SSM; Hoppenreijs EPAH; Armbrust W; van den Berg JM; Hissink Muller PCE; Tekstra J; Hoogendijk JE; Deakin CT; de Jager W; van Roon JAG; van der Pol WL; Nistala K; Pilkington C; de Visser M; Arkachaisri T; Radstake TRDJ; van der Kooi AJ; Nierkens S; Wedderburn LR; van Royen-Kerkhof A; van Wijk F
Arthritis Rheumatol; 2019 Aug; 71(8):1377-1390. PubMed ID: 30861625
[TBL] [Abstract][Full Text] [Related]
2. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis.
Wienke J; Pachman LM; Morgan GA; Yeo JG; Amoruso MC; Hans V; Kamphuis SSM; Hoppenreijs EPAH; Armbrust W; van den Berg JM; Hissink Muller PCE; Gelderman KA; Arkachaisri T; van Wijk F; van Royen-Kerkhof A
Arthritis Rheumatol; 2020 Jul; 72(7):1214-1226. PubMed ID: 32103637
[TBL] [Abstract][Full Text] [Related]
3. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis.
Bellutti Enders F; van Wijk F; Scholman R; Hofer M; Prakken BJ; van Royen-Kerkhof A; de Jager W
Arthritis Rheumatol; 2014 Aug; 66(8):2281-9. PubMed ID: 24756983
[TBL] [Abstract][Full Text] [Related]
4. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.
Reed AM; Peterson E; Bilgic H; Ytterberg SR; Amin S; Hein MS; Crowson CS; Ernste F; Gillespie EB
Arthritis Rheum; 2012 Dec; 64(12):4078-86. PubMed ID: 22886447
[TBL] [Abstract][Full Text] [Related]
5. Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk.
Wienke J; Mertens JS; Garcia S; Lim J; Wijngaarde CA; Yeo JG; Meyer A; van den Hoogen LL; Tekstra J; Hoogendijk JE; Otten HG; Fritsch-Stork RDE; de Jager W; Seyger MMB; Thurlings RM; de Jong EMGJ; van der Kooi AJ; van der Pol WL; ; Arkachaisri T; Radstake TRDJ; van Royen-Kerkhof A; van Wijk F
Rheumatology (Oxford); 2021 Feb; 60(2):785-801. PubMed ID: 32810267
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM
Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus.
Enocsson H; Wetterö J; Eloranta ML; Gullstrand B; Svanberg C; Larsson M; Bengtsson AA; Rönnblom L; Sjöwall C
Front Immunol; 2021; 12():688753. PubMed ID: 34276678
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.
Niewold TB; Kariuki SN; Morgan GA; Shrestha S; Pachman LM
Arthritis Rheum; 2009 Jun; 60(6):1815-24. PubMed ID: 19479879
[TBL] [Abstract][Full Text] [Related]
9. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
Bauer JW; Petri M; Batliwalla FM; Koeuth T; Wilson J; Slattery C; Panoskaltsis-Mortari A; Gregersen PK; Behrens TW; Baechler EC
Arthritis Rheum; 2009 Oct; 60(10):3098-107. PubMed ID: 19790071
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.
Almeida B; Campanilho-Marques R; Arnold K; Pilkington CA; Wedderburn LR; Nistala K;
Arthritis Rheumatol; 2015 Sep; 67(9):2495-502. PubMed ID: 25988361
[TBL] [Abstract][Full Text] [Related]
11. Serum and urinary galectin-9 and C-X-C motif chemokine ligand 10.
Mehta P; Singh P; Aggarwal A
Lupus; 2022 Apr; 31(4):482-487. PubMed ID: 35245170
[TBL] [Abstract][Full Text] [Related]
12. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis.
Huard C; Gullà SV; Bennett DV; Coyle AJ; Vleugels RA; Greenberg SA
Br J Dermatol; 2017 May; 176(5):1224-1230. PubMed ID: 27564228
[TBL] [Abstract][Full Text] [Related]
13. Interferon-inducible chemokines reflect severity and progression in sarcoidosis.
Su R; Nguyen ML; Agarwal MR; Kirby C; Nguyen CP; Ramstein J; Darnell EP; Gomez AD; Ho M; Woodruff PG; Koth LL
Respir Res; 2013 Nov; 14(1):121. PubMed ID: 24199653
[TBL] [Abstract][Full Text] [Related]
14. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis.
Chen M; Quan C; Diao L; Xue F; Xue K; Wang B; Li X; Zhu X; Zheng J; Cao H
Br J Dermatol; 2018 Dec; 179(6):1334-1341. PubMed ID: 30101523
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
16. Correlation of PMN elastase and PMN elastase-to-neutrophil ratio with disease activity in patients with myositis.
Wu S; Peng W; Zhang Y; Guo J; Fu J; Wang W
J Transl Med; 2019 Dec; 17(1):420. PubMed ID: 31842908
[TBL] [Abstract][Full Text] [Related]
17. Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.
Shih Y; Chen S; Huang J; Chen Y; Zhu Z; Zhao Q; Zhao X; Xue F; Xiang J; Chen X; Zhu X; Pan M; Wu J; Zheng J; Li H; Cao H
Rheumatology (Oxford); 2024 Jan; 63(1):251-258. PubMed ID: 37184873
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of von Willebrand factor in patients with adult dermatomyositis.
Komiya T; Negoro N; Kondo K; Miura K; Hirota Y; Yoshikawa J
Clin Rheumatol; 2005 Aug; 24(4):352-7. PubMed ID: 15565394
[TBL] [Abstract][Full Text] [Related]
19. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.
Pinal-Fernandez I; Mecoli CA; Casal-Dominguez M; Pak K; Hosono Y; Huapaya J; Huang W; Albayda J; Tiniakou E; Paik JJ; Johnson C; Danoff SK; Corse AM; Christopher-Stine L; Mammen AL
Neurology; 2019 Nov; 93(19):e1768-e1777. PubMed ID: 31594859
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study.
Hasija R; Pistorio A; Ravelli A; Demirkaya E; Khubchandani R; Guseinova D; Malattia C; Canhao H; Harel L; Foell D; Wouters C; De Cunto C; Huemer C; Kimura Y; Mangge H; Minetti C; Nordal EB; Philippet P; Garozzo R; Martini A; Ruperto N;
Arthritis Rheum; 2011 Oct; 63(10):3142-52. PubMed ID: 21647864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
